Drugs · acquisition-cost intelligence
ASMANEX
Mometasone Furoate· ingredient mometasoneCorticosteroids· MOMETASONE FUROATE 110 ug/1; MOMETASONE FUROATE 220 ug/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$104.30
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other mometasone products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Mometasone furoate | $0.26779 | −$104.03 |
| Mometasone Furoate | $0.34950 | −$103.95 |
| Mometasone Furoate | $0.48662 | −$103.81 |
| allergy | $1.43 | −$102.86 |
| ASMANEX HFA | $7.38 | −$96.92 |
| Ryaltris | $7.69 | −$96.61 |
| Dulera | $25.23 | −$79.06 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.